+

WO2009008666A3 - Cellule dendritique autologue médiatisée par une thérapie photodynamique ayant l'aptitude d'inhiber la croissance d'une tumeur - Google Patents

Cellule dendritique autologue médiatisée par une thérapie photodynamique ayant l'aptitude d'inhiber la croissance d'une tumeur Download PDF

Info

Publication number
WO2009008666A3
WO2009008666A3 PCT/KR2008/004042 KR2008004042W WO2009008666A3 WO 2009008666 A3 WO2009008666 A3 WO 2009008666A3 KR 2008004042 W KR2008004042 W KR 2008004042W WO 2009008666 A3 WO2009008666 A3 WO 2009008666A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
suppress
growth
photodynamic therapy
dendritic cell
Prior art date
Application number
PCT/KR2008/004042
Other languages
English (en)
Other versions
WO2009008666A2 (fr
Inventor
Dae-Seog Lim
Ju-Ah Jeong
Hyun-Soo Lee
Yong-Soo Bae
Original Assignee
Creagene Inc
Kang Mi Sun
Dae-Seog Lim
Ju-Ah Jeong
Hyun-Soo Lee
Yong-Soo Bae
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creagene Inc, Kang Mi Sun, Dae-Seog Lim, Ju-Ah Jeong, Hyun-Soo Lee, Yong-Soo Bae filed Critical Creagene Inc
Publication of WO2009008666A2 publication Critical patent/WO2009008666A2/fr
Publication of WO2009008666A3 publication Critical patent/WO2009008666A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention porte sur des cellules dendritiques (DC) matures ayant une aptitude améliorée d'induire des réponses immunitaires anti-tumeur, et sur un procédé pour la préparation des DC mentionnées ci-dessus par la procédure d'impulsion de DC immatures avec des lysats de cellules cancéreuses sur lesquelles une thérapie photodynamique (PDT) a été conduite. La cellule dendritique de cette invention acquiert une activité pour induire des réponses immunitaires anti-tumorales de telle sorte qu'elle exerce un effet remarquable pour inhiber la croissance d'une tumeur.
PCT/KR2008/004042 2007-07-09 2008-07-09 Cellule dendritique autologue médiatisée par une thérapie photodynamique ayant l'aptitude d'inhiber la croissance d'une tumeur WO2009008666A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2007-0068524 2007-07-09
KR1020070068524A KR100954315B1 (ko) 2007-07-09 2007-07-09 종양성장 억제능을 갖는 광역동성 치료 매개 자가 유래수지상 세포

Publications (2)

Publication Number Publication Date
WO2009008666A2 WO2009008666A2 (fr) 2009-01-15
WO2009008666A3 true WO2009008666A3 (fr) 2009-03-19

Family

ID=40229274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/004042 WO2009008666A2 (fr) 2007-07-09 2008-07-09 Cellule dendritique autologue médiatisée par une thérapie photodynamique ayant l'aptitude d'inhiber la croissance d'une tumeur

Country Status (2)

Country Link
KR (1) KR100954315B1 (fr)
WO (1) WO2009008666A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371053A4 (fr) 2008-12-17 2013-07-17 Discovery Technology International Inc Moteur piézo-électrique avec couple élevé

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOLLNICK S.O. ET AL.: "Generation of effective antitumor vaccines using photodynamic therapy", CANCER RES., vol. 62, 2002, pages 1604 - 1608 *
GOMER C.J. ET AL.: "Photodynamic therapy-mediated oxidative stress can induce expression of heat shock proteins", CANCER RES., vol. 56, 1996, pages 2355 - 2360 *

Also Published As

Publication number Publication date
KR20090005472A (ko) 2009-01-14
KR100954315B1 (ko) 2010-04-21
WO2009008666A2 (fr) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2014028453A3 (fr) Cellules tueuses naturelles et leurs utilisations
WO2021062227A3 (fr) Compositions et procédés pour le traitement de cancers liquides
MX350795B (es) Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
SG170006A1 (en) Monoclonal antibodies against cd30 lacking fucosyl residues
WO2006089231A3 (fr) Anticorps monoclonaux diriges contre l'antigene d'enveloppe specifique de la prostate (psma) depourvus de residus fucosyle
WO2014004427A3 (fr) Anticorps anti-egfr et leurs utilisations
WO2007084672A3 (fr) Anticorps monoclonaux anti-cd30 dépourvus de résidus fucosyl et xylosyl
WO2011050302A3 (fr) Procédés et formulations nutritionnels permettant d'augmenter l'efficacité et de réduire les effets secondaires du traitement du cancer
WO2007039192A3 (fr) Compositions et methodes pour traiter des tumeurs ayant des antigenes de survivine
EP4339287A3 (fr) Cellules modifiées et procédés de thérapie
WO2007056540A3 (fr) Traitement anti-tnf$g(a) destine a traiter l'enterocolite associee a un traitement par anticorps therapeutique immunostimulateur
PH12014501836A1 (en) Novel adjuvant compositions
WO2011130566A3 (fr) Méthode de traitement de tumeurs solides
WO2005081854A3 (fr) Peptides d'epitopes du recepteur d'egf et ses applications
EP2580213A4 (fr) 8-(hétéroarylméthyl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc
WO2012116225A3 (fr) Vaccin glycolipopeptidique à base de muc1 comportant un adjuvant
TN2011000219A1 (en) Extract of aerial parts of oats harvested before ear emergence
EP2095775A4 (fr) Appareil de blocage d'une conduction électrique anormale par thérapie photodynamique (tpd)
WO2013058838A3 (fr) Formulations d'anti-oxydant à libération prolongée, injectables ou implantables de manière commode, pour des thérapies de maladies oculaires ou de cancer
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
WO2006047515A3 (fr) Cellules dendritiques chargees de corps cellulaires de melanome de choc thermique
WO2012020100A3 (fr) Compositions et procédés de production de cellules dendritiques
WO2009032256A3 (fr) Activateurs d'apc en combinaison avec une cellule sécrétant des cytokines et procédés pour les utiliser
WO2009008666A3 (fr) Cellule dendritique autologue médiatisée par une thérapie photodynamique ayant l'aptitude d'inhiber la croissance d'une tumeur
EP4061409A4 (fr) Stimuli hyperactivant des cellules dendritiques résidentes pour l'immunothérapie anticancéreuse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08778702

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08778702

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载